Korea Continues Crackdown On Pharma Kickbacks; First Doctor Sentenced To Jail
This article was originally published in PharmAsia News
Executive Summary
After a year on the books, Korea’s new anti-rebate law nabs its first healthcare professional.
You may also be interested in...
Korea's Antitrust Watchdog Says Rebates Continuing Despite New Law; Levies $11 Million In Fines
SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year
South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law
SEOUL - South Korea's Ministry of Health and Welfare outlined detailed provisions to implement a new "anti-rebate law," which will enable courts to punish both contributors and receivers of rebates. Passed overwhelmingly by South Korea's National Assembly on April 28, the law goes into effect Nov. 28, and will be enforced by the ministry.Under the new regulations, pharmas will be able to offer "sample" drugs as long as they are offered the "minimum packing unit," said the ministry, adding that they will also be able to offer minimal amounts of drugs and research fees to those conducting clinical trials
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.